[시장보고서]세계의 크론병 치료 시장 - 규모, 점유율, 동향 분석 보고서 : 유형별, 투여 경로별, 유통 채널별, 지역별, 부문 예측(2024-2030년)

세계의 크론병 치료 시장 - 규모, 점유율, 동향 분석 보고서 : 유형별, 투여 경로별, 유통 채널별, 지역별, 부문 예측(2024-2030년)

Crohn´s Disease Therapeutics Market Size, Share & Trends Analysis Report By Type, By Route of Administration (Injectable, Oral), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030

상품코드 : 1553575

리서치사 : Grand View Research, Inc.

발행일 : 2024년 08월

페이지 정보 : 영문 100 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,443,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 9,862,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,700,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

크론병 치료 시장의 성장과 동향

크론병 치료 세계 시장 규모는 2030년에 162억 8,000만 달러에 달할 것으로 예측되고, 2024-2030년의 CAGR은 2.7%로 성장할 것으로 예측됩니다.

이 질병에 대한 인식 증가와 신규 치료법의 개발에 대한 규제 당국의 이니셔티브 증가가 함께 시장은 높은 성장 가능성을 갖고 있다고 추정됩니다.

예를 들어, 미국 소화기 병학회(AGA)는 화이자와 공동으로 염증성 장 질환과 관련된 연구 프로젝트를 지원하고 그 이름으로 3개의 보조금을 제공합니다. Crohn's & Colitis Foundation, European Federation of Crohn's & Ulcerative Colitis Associations, American Autoimmune Related Diseases Association 등은 연구 자금을 제공하는 조직의 일부입니다.

또한 크론병의 유병률이 증가함에 따라 많은 기업들이 다양한 규제기관 및 연구기관과 협력하여 크론병에 대한 신규하고 효과적인 치료법의 도입을 추진하고 있습니다. 2016년에는 Pfizer의 치료 혁신 센터(CTI)가 존스 홉킨스 대학과 협력하여 크론병과 궤양성 대장염을 치료하는 신약을 발견했습니다.

크론병 치료 시장 보고서 하이라이트

크론병을 효과적으로 관리하는 강력한 생물학적 요법과 바이오시밀러의 개발에 의한 약물 요법의 진보로 비외과적 요법이 시장을 독점하고 2023년에는 70.3%의 점유율을 차지합니다.
북미의 크론병 치료는 2023년 세계 수익의 60.25%를 차지하며 시장을 독점하고 있습니다. 크론병 환자의 발병률의 높이는 주요 촉진요인 중 하나입니다.
이 시장의 주요 진출기업으로는 Johnson & Johnson Services Inc., Pfizer Inc., Allergan, AbbVie Inc. 등이 있습니다.

크론병 치료 시장 점유율, 지역별, 2023년과 2030년, 100만 달러
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 남아프리카
- 쿠웨이트

제8장 경쟁 구도

주요 시장 진출기업에 의한 최근의 동향과 영향 분석
기업 분류
기업 히트맵 분석
기업 프로파일
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
- Perrigo Company plc
- Pfizer Inc.
- Johnson &Johnson Services Inc.
- Ferring BV
- Bristol-Myers Squibb Company(Celgene Corporation)
- F. Hoffmann-La Roche Ltd(Genentech, Inc.)
- UCB SA
- Salix Pharmaceuticals
- Gilead Sciences Inc.

JHS

영문 목차

영문목차

Crohn's Disease Therapeutics Market Growth & Trends:

The global crohn's disease therapeutics market size is expected to reach USD 16.28 billion in 2030 and is projected to grow at a CAGR of 2.7% from 2024 to 2030. Increasing awareness of the disease, coupled with rising initiatives by regulatory bodies for development of novel treatment options, is estimated to provide the market with high growth potential.

For instance, the American Gastroenterological Association (AGA), in collaboration with Pfizer, supports research projects related to inflammatory bowel diseases and has offered three grants in their name. The Crohn's & Colitis Foundation, European Federation of Crohn's & Ulcerative Colitis Associations, and American Autoimmune Related Diseases Association are some of the organizations providing funds for research.

Furthermore, increase in prevalence of Crohn's disease has directed many companies to collaborate with various regulatory bodies and research institutes to introduce novel and effective treatment for the condition. In 2016, Pfizer's Centers for Therapeutic Innovation (CTI) collaborated with Johns Hopkins University to discover new medicines to treat Crohn's disease and ulcerative colitis.

Crohn's Disease Therapeutics Market Report Highlights:

Non-surgical dominated the market and accounted for a share of 70.3% in 2023 owing to the advancements in medication and the development of powerful biological therapies and biosimilars that effectively manage Crohn's disease
North America crohn's disease therapeutics dominated the market in 60.25% of the global revenue in 2023. High incidences of Chron's in patients are one of the major growth drivers
Some of the key players in the market are Johnson & Johnson Services Inc.; Pfizer Inc.; Allergan; and AbbVie Inc.

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Crohn's Disease Therapeutics Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Crohn's Disease Therapeutics Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Crohn's Disease Therapeutics Market: Type Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Crohn's Disease Therapeutics Market: Type Movement Analysis, USD Million, 2023 & 2030
4.3. Non-Surgical
- 4.3.1. Non-Surgical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  - 4.3.1.1. Anti-inflammatory Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  - 4.3.1.2. Immune System Suppressors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  - 4.3.1.3. Antibiotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  - 4.3.1.4. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Surgical
- 4.4.1. Surgical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Crohn's Disease Therapeutics Market: Route of Administration Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Crohn's Disease Therapeutics Market: Route of Administration Movement Analysis, USD Million, 2023 & 2030
5.3. Injectable
- 5.3.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Oral
- 5.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Crohn's Disease Therapeutics Market: Distribution Channel Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Crohn's Disease Therapeutics Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
6.3. Hospital Pharmacies
- 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacies
- 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Online Pharmacies
- 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Crohn's Disease Therapeutics Market: Regional Estimates & Trend Analysis

7.1. Crohn's Disease Therapeutics Market Share, By Region, 2023 & 2030, USD Million
7.2. North America
- 7.2.1. North America Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
  - 7.2.3.1. Canada Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
- 7.3.1. Europe Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. UK
  - 7.3.2.1. UK Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
  - 7.3.3.1. Germany Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
  - 7.3.4.1. France Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.5. Italy
  - 7.3.5.1. Italy Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.6. Spain
  - 7.3.6.1. Spain Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
  - 7.3.7.1. Denmark Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
  - 7.3.8.1. Sweden Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9. Norway
  - 7.3.9.1. Norway Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. China
  - 7.4.2.1. China Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Japan
  - 7.4.3.1. Japan Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
  - 7.4.4.1. India Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. South Korea
  - 7.4.5.1. South Korea Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. Australia
  - 7.4.6.1. Australia Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
  - 7.4.7.1. Thailand Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
- 7.5.1. Latin America Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Argentina
  - 7.5.3.1. Argentina Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Saudi Arabia
  - 7.6.2.1. Saudi Arabia Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. UAE
  - 7.6.3.1. UAE Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. South Africa
  - 7.6.4.1. South Africa Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
  - 7.6.5.1. Kuwait Crohn's Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
- 8.4.1. Takeda Pharmaceutical Company Limited
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Recent Developments/Strategic Initiatives
- 8.4.2. AbbVie Inc.
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Recent Developments/Strategic Initiatives
- 8.4.3. Perrigo Company plc
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Recent Developments/Strategic Initiatives
- 8.4.4. Pfizer Inc.
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Recent Developments/Strategic Initiatives
- 8.4.5. Johnson & Johnson Services Inc.
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Recent Developments/Strategic Initiatives
- 8.4.6. Ferring B.V.
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Recent Developments/Strategic Initiatives
- 8.4.7. Bristol-Myers Squibb Company (Celgene Corporation)
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Recent Developments/Strategic Initiatives
- 8.4.8. F. Hoffmann-La Roche Ltd (Genentech, Inc.)
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Recent Developments/Strategic Initiatives
- 8.4.9. UCB S.A.
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Recent Developments/Strategic Initiatives
- 8.4.10. Salix Pharmaceuticals
  - 8.4.10.1. Participant's Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Recent Developments/Strategic Initiatives
- 8.4.11. Gilead Sciences Inc.
  - 8.4.11.1. Participant's Overview
  - 8.4.11.2. Financial Performance
  - 8.4.11.3. Product Benchmarking
  - 8.4.11.4. Recent Developments/Strategic Initiatives

한글목차

크론병 치료 시장의 성장과 동향

크론병 치료 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 크론병 치료 시장의 변수, 동향, 범위

제4장 크론병 치료 시장 : 유형별, 추정·동향 분석

제5장 크론병 치료 시장 : 투여 경로별, 추정·동향 분석

제6장 크론병 치료 시장 : 유통 채널별, 추정·동향 분석

제7장 크론병 치료 시장 :지역별, 추정·동향 분석